Under the BC Biosimilars Initiative whose implementation started in May 2019, British Columbia PharmaCare announced on August 21, 2020 that it is changing coverage of rituximab medicines for PharmaCare covered patients, including patients on rituximab for rheumatoid arthritis. In consultation with their healthcare professional, patients currently covered for the original-brand rituximab will switch to a rituximab biosimilar such as Riximyo® within six months for continued coverage.
Click here for more details on BC Biosimilars switch policy for rituximab and to read B.C. Ministry of Health’s news release.
Novartis and Sandoz are responding to the coronavirus situation with safety of associates and patients our primary concern. We are also supporting communities, contributing to research efforts and keeping generic medicine prices stable.
